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The 14th Annual Meeting of ‘‘Skin Care
in Organ Transplant Patients Europe’’
(SCOPE), a society formed by a group of
European dermatologists interested in
skin disease in organ transplant recipi-
ents (OTRs), was held in Leiden, The
Netherlands, from 15 to 18 May 2014.
The need for this interest group stems
from the increasing numbers of OTRs
and their increasing longevity, resulting
in markedly increased numbers of squa-
mous cell carcinoma of the skin (SCC)
and other benign and malignant skin
conditions. On the one hand, most
experts believe OTRs to be a model
group for SCC development where
mechanisms such as chronic sun
damage apply to the general population
as well, making OTRs a proof-of-con-
cept group with much accelerated cuta-
neous carcinogenesis. On the other
hand, OTRs present with unique mecha-
nisms such as non-immunologic effects
of immunosuppressants and increased
microbial, in particular viral counts,
distinguishing OTR from the general
population. Presentations at the SCOPE
meeting thus reported findings from
both OTR and the general population,
as indicated below, to improve our
understanding.
The epidemiology of basal cell carci-
noma (BCC) in OTRs in Sweden was
summarized by Britta Krynitz from the
Karolinska Institute in Stockholm, Swe-
den. The nationwide database allows
the study of expected and true incidence
of BCC. Since 2004, BCC has system-
atically been registered on the basis of
pathology reports. Histological grading
into four types reflecting clinically
aggressive behavior was used. A total
of 7213 OTRs (63% kidney transplant
recipients (KTR), 37% females) with a
mean follow-up time of 6.4 years devel-
oped 1290 BCCs in total. A first cohort,
who underwent transplantion between
2004 and 2011, included 4023 OTRs
with 341 BCCs in 175 OTRs, whereas
the second cohort, transplanted from
1994 to 2003, contained 3190 OTRs
with 429 OTRs developing 949 BCCs.
The standardized incidence ratios (SIR)
for BCC were 6 (cohort 1) and 9 (cohort
2). OTR transplanted at a younger age
(o45 years) showed an even higher SIR
in the range of 10. The anatomical
distribution was mainly to the head
and neck followed by the trunk in both
genders. In females, preponderance for
the trunk in comparison with the general
population was shown. Histological
types were evenly split into nodular,
superficial, and infiltrative BCC, similar
to the general population. A history of
melanoma and SCC before transplanta-
tion was associated with a fivefold and
sevenfold increased risk for subsequent
BCC, respectively. When comparing risk
for BCC with the risk for SCC (SIR of 6
for BCC and an SIR of 100 for SCC),
there was a 17-fold increased risk for
SCC versus BCC in the OTRs analyzed.
Structured analyses of OTR cohorts
are important for a better under-
standing of this special patient group.
Alexandra Geusau, Allgemeines Kran-
kenhaus, Vienna, Austria, reported on a
monocentric cohort of 1130 patients
with a median age of 56 years enrolled
from 2000 to 2013. Heart transplant
recipients (HTRs) made up 43%, liver
transplant recipients 11%, lung trans-
plant recipients (LTR) 17%, and KTRs
29%, with a median follow-up of 4.3
years. A total of 314 non-melanoma skin
cancers (NMSC) occurred in 102 OTRs,
translating into 10.1 NMSCs per 100
patient-years in HTR, 10.3 NMSCs per
100 patient-years for liver transplant,
20.3 NMSCs per 100 patient-years for
lung transplant, and 16.2 NMSCs per
100 patient-years for KTRs. Gender,
older age at transplantation, and lighter
skin type were associated with
increased SCC. Bacterial infections
occurred in 16.1% of OTRs across all
organs transplanted. Candida infection
occurred in 9.2% and dermatophyte
infection in 5.6% of OTRs, where KTRs
suffered more Candida infections.
A retrospective cohort showing an
increased incidence of skin cancer in
comparison with other malignancies for
HTR in the Czech Republic was
reported by Zuzana Secˇnı´kova´, Bulovka
Hospital, Prague, Czech Republic. A
total of 603 HTRs (81.8% males) were
included. Dilated cardiomyopathy was
the underlying condition before heart
transplantation in half of the HTRs.
Median time to diagnosis of NMSC
was 10 years. A total of 119 cases of
skin cancer with a median follow-up of
6.3 years were observed in 67 patients
(61 males). SCC was most abundant,
with 62 tumors (52%) arising. Skin
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cancers made up half of all cancers
occurring in this HTR cohort, where
lung cancer, gastrointestinal, and post-
transplant lymphoproliferative disorders
were most frequent among the non-
cutaneous cancers.
Risk factors in LTRs for skin cancer
were reported by Chantal Bachmann,
University Hospital, Zu¨rich, Switzer-
land. A retrospective cohort analyzed
risk factors in the first year after trans-
plantation for SCC development in sub-
sequent years. A total of 205 LTRs were
included (female 51%, median age at
transplantation 48 years). SCC occurred
in a linear manner with 17% of LTRs at
5-year, 34% at 10-year, and 60% at
15-year follow-up affected by SCC.
Cytomegalovirus (CMV) reactivation
was associated with a 4.2-fold increased
risk for SCC. Each instance of CMV
reactivation doubled the risk for subse-
quent SCC. There was a dose–response
relationship for every day of CMV repli-
cation and SCC incidence. Moxifloxacin
use was associated with a 2.9-fold
increased risk for SCC and showed a
dose–response relationship for SCC
incidence.
Clinical exposure to voriconazole is
known to result in pronounced photo-
sensitization and aggressive SCC forma-
tion with a short delay. The effect of
voriconazole on keratinocyte viability
in vitro was studied by Ahmad Jalili,
Allgemeines Krankenhaus, Vienna, Aus-
tria. In vitro, adding all-trans retinoic
acid and voriconazole to keratinocytes
increased the absorbance of UVA and
UVB. The viability and proliferation of
keratinocytes and organotypic cultures
were not affected by voriconazole, sug-
gesting other mechanisms for the effect
of voriconazole on the skin.
The efficacy of rapamycin in the
prevention of future SCC was studied
in a prospective study on renal trans-
plant recipients switching from calci-
neurin inhibitors. The 2-year results
published in NEJM 2012 showed a
benefit of such a switch for low tumor
load. Sylvie Euvrard, Hoˆpital Edouard
Herriot, Lyon, France, now reported the
5-year follow-up of this study group. A
total of 129 KTRs were enrolled at 61
years of median age with a mean dura-
tion of transplantation of 12 years.
Eighty-three KTRs could be assessed at
5-year follow-up. In the case of 51
KTRs with a single SCC only at
switch, SCC had recurred in 10% of
rapamycin-treated KTR versus 44% of
calcineurin-inhibitor–treated KTRs. For
32 KTRs with multiple SCCs at switch,
SCC had recurred in 18% of patients
in the rapamycin-treated KTR group
versus 62% of calcineurin-inhibitor–
treated KTRs. Renal function remained
unchanged.
The impact of ethnicity and skin
disease in OTRs is little explored and
was analyzed at the transplantation cen-
ter of Johns Hopkins University, Balti-
more, USA. Liliane Borik showed that in
over 5,000 transplant recipients at this
center 33% were of non-Caucasian
ethnicity. Within these non-Caucasian
OTRs, the largest population of African
Americans was further analyzed. NMSC
occurred in 2.5% of African-American
OTRs, whereas 41% suffered bacterial,
17% fungal, and 19% viral infections of
the skin. Future algorithms for follow-up
should consider ethnicity for differential
recommendations and interventions.
Actinic keratosis (AK) in association
with field cancerization (FC) as a risk for
cutaneous SCC was the focus of a study
from Manchester, UK, conducted by
Wallingford, Lear, and Green. Charlotte
Proby from Dundee University, UK,
presented data gathered from question-
naires and skin exams in 452 kidney
transplant recipients transplanted at a
mean age of 52 years. In all 71% (323
of 452 patients) had no AK, and only
one of them (0.3%) developed SCC over
an 18-month prospective study com-
pared with 7% (4/60) with discrete AK
and 21% (15/70) with AK plus FC. The
odds ratios found 20-fold increased risk
when AK was present and 90-fold
increased risk when FC with AK was
present. Presence of AK with FC is thus a
strong indicator for future SCC events
and should be tackled with early inter-
vention.
Charlotte Proby from Dundee, UK,
reported genetic data from 20 cutaneous
SCC, in which exome sequencing was
performed. A high number of mutations,
10-fold higher than in any other solid
cancers, was identified. TP53 and
NOTCH gene mutations were the most
abundant findings. Exome sequencing
was validated in 102 SCCs using 454
deep sequencing of candidate genes.
454 sequencing identified NOTCH1
and/or NOTCH2 mutations in 82% of
SCCs analyzed, making these mutations
the most abundant in SCC. In a set of
BRAF inhibitor–induced SCCs, six out of
seven showed Notch1 mutations both in
the tumor and in adjacent skin. Notch-
mutated tumors showed no downstream
activation of the Notch pathway, con-
firming that these were deleterious
mutations.
Modern kinase inhibitors may show
paradoxical increase of skin tumors.
Vemurafenib inhibiting BRAFV600E
induces keratoacanthoma-like SCC.
Recent work of Catherine Harwood
and colleagues, presented by Charlotte
Proby, found that histological features
consistent with HPV infection including
koilocytosis could be identified in such
SCCs (10 out of 12 biopsies). Forty-five
skin tumors from seven such patients
demonstrated low levels of p53 muta-
tions contrasted by increased mutations
in HRAS (15/45 SCC). Although HPV
DNA could be detected in the majority
(80%; 36/45) of these vemurafenib-asso-
ciated skin lesions, only a minority (1/11
SCC, and 6/18 squamoproliferative
lesions) contained viral loads indicative
of active infection. Despite the presence
of koilocytosis, the low viral copy num-
ber speaks against a substantial role for
HPV in BRAF inhibitor–induced skin
lesions.
Innate immunity may be fundamental
in controlling cutaneous carcinogenesis
in OTR, as adaptive immunity is sub-
dued by immunosuppressants. Single
nucleotide polymorphism analysis was
reported by Piotr Dziunycz, University
Hospital, Zu¨rich, Switzerland, in 1119
OTR in a selected set of innate immu-
nity genes. Although SCC development
before transplantation showed no asso-
ciation, SCC development after trans-
plantation was associated with
polymorphisms in the IL1alpha and
IL1beta genes with a hazard ratio of
2.81 and 5.02, respectively. On the
basis of the findings in other solid
cancers, the hypothesis was raised that
inflammasome activation may contri-
bute to SCC formation in OTR.
Prediction of an aggressive course in
SCC for OTRs is difficult for lack
of defined predicting histopathological
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characteristics. Jean Kanitakis, Hoˆpital
Eduard Herriot, Lyon, France, reported
that among 1200 SCCs 34 primary,
aggressive SCCs were diagnosed in 32
OTR, with later recurrences in 20 cases
and metastasis in 14 cases. These were
pathologically studied in comparison
with 25 matched, but nonaggressive,
SCCs of the same OTR group. An overall
62% of primary, aggressive SCC cases
were localized on the head and neck.
Clark level was associated with poor
outcome.
Macrophages contribute to tumor for-
mation in many cancers. Anne Marie
Rhebergen, Yale University, New
Haven, USA, summarized the analyses
of tumor-associated macrophages in
SCCs of OTRs. Lactic acid stimulation
induces VEGF and Arginase-I expression
in macrophages, resulting in M2 polar-
ization with increased tumor growth in
the mouse. Macrophage density in
human SCCs was fourfold increased
compared with BCCs and is observed
early in carcinogenesis at the in-situ
stage. Macrophage density was half in
SCC in situ in OTRs compared with
immunocompetent patients. Peritumoral
macrophages showed an M2 polariza-
tion in immunocompetent patients but
not in OTRs.
Tumor staging in SCC according to
the American Joint Committee on Can-
cer (AJCC) confers little distinctive
potential for the majority of tumors.
Chrysalyne Schmults, Harvard Univer-
sity, Boston, USA, reported an alterna-
tive staging system, the Brigham and
Women’s Hospital (BWH) Staging Sys-
tem, which allows for appropriate upsta-
ging of tumors with high risks of
metastasis and death. Clinical diameter
2 cm or larger, depth beyond fat, poor
differentiation, and perineural invasion
of nerves of 0.1 mm diameter or more
were set as the criteria for classification.
Lack of risk factors resulted in 0.2% risk
of local recurrence. Tumors with one
risk factor (BWH T2a) had a 2% risk of
nodal disease and 1% risk of SCC death.
Tumors with multiple risk factors (BWH
T2b/T3) had a 10-year risk of nodal
metastasis of 20% and 10-year risk of
SCC death of 8%. In all, fifty-two per-
cent of immunosuppressed patients had
multiple tumors compared with 22% in
immunocompetent patients, whereas
there were no differences in metastasis
and SCC death.
Kaposi’s sarcoma (KS) is an HHV-8-
induced tumor of lymphatic endothelial
cells with increased incidence in
immunosuppression. Ce´leste Lebbe´,
Hoˆpital St Louis, Paris, France, summar-
ized 89 KTRs affected by KS diagnosed
at 18 months after transplantation
on average. Complete remission was
reached in 27% and progression was
observed in 8% following reduction
of immunosuppression and switch to
mTOR inhibitors. Systemic treatment
with liposomal doxorubicin, bleomycin,
and taxol resulted in side effects in
30–42% of patients. Risk factors for
relapse were previous relapse and
use of mTOR inhibitors. Patient
survival was 86% at 5 years and 71%
at 10 years. There were no deaths
due to KS, but 19% of deaths were
related to treatment-associated adverse
events.
HPV associates with SCC in OTR, but
the exact mechanisms are still unclear.
Roel Genders, Leiden University
Medical Center, Leiden, The Nether-
lands, reported on the correlation of
human beta papillomavirus serology
and subsequent SCC risk. A total of
445 patients were examined with 1880
sera spanning the time from 1 year
before until 1 year after transplantation
with a clinical follow-up of up to 22
years. OTRs with skin cancer were
seroreactive in 88% of cases compared
with 71% of seropositive patients naive
for skin cancer. The hazard ratio
was 2.95 for keratinocyte carcinomas
overall. After adjustment for age, sex,
and organ transplanted, the hazard ratio
was 3.2 for either SCC or BCC formation
when seroreactivity was present around
the transplantation.
Polyomaviruses have recently been
recognized in Merkel cell carcinoma
and other skin diseases with varying
degrees of causal correlation. Expanding
the body of knowledge, Mariet Felt-
kamp, Leiden University Medical Cen-
ter, Leiden, The Netherlands, addressed
polyomavirus seropositivity in 799 sera
of immunocompetent Australians across
all ages by Luminex analysis. Seropre-
valences in the cohort studied were
68% for Merkel Cell polyoma virus,
81% for Trichodysplasia spinulosa–
associated polyomavirus, 76% for
human polyomavirus (HPyV)-6, 66%
for HPyV-7, 24% for HPyV-9, and
almost 100% for BK polyoma virus.
Analyzing a cohort of 101 Dutch KTRs,
seroconversion after transplantation was
particularly seen for HPyV-9. Viral DNA
could be detected in plasma, indicating
active HPyV-9 replication in these
patients.
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